Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Biorepair Parodontgel Intensive is a specialized oral care formulation developed by Coswell S.p.A. to address gum inflammation and promote tooth remineralization. Its primary technology is **microRepair®**, which consists of biomimetic zinc hydroxyapatite crystals that bond to tooth enamel and dentin, filling micro-cracks and creating a protective mineral barrier against acid erosion and bacterial biofilm. The formulation is enhanced with hyaluronic acid to support mucosal hydration and tissue regeneration, and lactoferrin, an antimicrobial protein that sequesters iron to inhibit the growth of periodontopathogenic bacteria. It is clinically indicated for the management of gingivitis, periodontitis, and post-surgical recovery, providing both a structural repair of the enamel and an anti-inflammatory effect on the periodontal tissues.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Biorepair Parodontgel Intensive.